
Sign up to save your podcasts
Or


In this edition, we have Dr. Teele Kuusk (UK), the associate editor of the UROONCO RCC educational platform discussing kidney cancer highlights at the recent ESMO2022.
Dr. Kuusk begins with the reporting of several new trials and the accompanying results, which include: Phase 3 CheckMate-914, Phase 3 COSMIC-313, Phase 2 Keynote-B61, and Cohort 1 of LITESPARK-003 study.
After delivering the trial results, Dr. Kuusk shares the possible reasons why the adjuvant trials failed.
For more details on the results of the LITESPARK-003 study, you can watch this video featuring Assoc. Prof. Jaime Merchan (US), who presented at ESMO2022. https://kidney.uroonco.uroweb.org/video/cohort-1-of-litespark-003/
This article was first posted on UROONCO.
By European Association of Urology3.7
33 ratings
In this edition, we have Dr. Teele Kuusk (UK), the associate editor of the UROONCO RCC educational platform discussing kidney cancer highlights at the recent ESMO2022.
Dr. Kuusk begins with the reporting of several new trials and the accompanying results, which include: Phase 3 CheckMate-914, Phase 3 COSMIC-313, Phase 2 Keynote-B61, and Cohort 1 of LITESPARK-003 study.
After delivering the trial results, Dr. Kuusk shares the possible reasons why the adjuvant trials failed.
For more details on the results of the LITESPARK-003 study, you can watch this video featuring Assoc. Prof. Jaime Merchan (US), who presented at ESMO2022. https://kidney.uroonco.uroweb.org/video/cohort-1-of-litespark-003/
This article was first posted on UROONCO.

325 Listeners

504 Listeners

55 Listeners

39 Listeners

99 Listeners

83 Listeners

285 Listeners

39 Listeners

58 Listeners

2 Listeners

86 Listeners

55 Listeners

13 Listeners

0 Listeners

14 Listeners